On March 20, 2012, the U.S. Supreme Court issued its ruling in Mayo Collaborative Services v. Prometheus Laboratories, Inc., striking down patent claims directed to methods of optimizing patient treatment in which the level of a certain drug metabolite is measured to identify a need to increase or decrease dosage levels. The unanimous decision authored by Justice Breyer reversed the Federal Circuit’s finding of patent-eligibility based on the claims embracing the transformative steps of “administering” a drug and “determining” metabolite levels.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.